Results 171 to 180 of about 1,406,007 (316)

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes. [PDF]

Br J Haematol
Cholack GA, Mwangi R, Vodička P, Habermann TM, Hinder V, Robinson DP, Feldman AL, Witzig TE, Villasboas JC, Ansell SM, Link BK, Wang Y, Thompson CA, Slager SL, Maurer M, Novak AJ, Cerhan JR.   +16 more
europepmc   +1 more source

Importin 7 mediates the nuclear import of HIV‐1 integrase via a specific interacting interface

FEBS Open Bio, EarlyView.
HIV‐1 integrase enables viral DNA integration into the host genome. By binding to the core domain of the host protein Importin 7 via its C‐terminal domain, the integrase is transported across the nuclear membrane into the nucleus, where integration of the viral genome into host DNA takes place. This translocation is a critical step for subsequent viral
Juana Bana, Avigail Yariv, Tal Oppenheim, Hadar Amartely, Dana Reichmann, Oded Livnah   +5 more
wiley   +1 more source

Family history of diabetes and glycemic progression: A propensity score-based analysis using health checkup data. [PDF]

PLoS One
Oh S, Kim S, Yun J, Min JK, Jee HJ, Heo TY.   +5 more
europepmc   +1 more source

Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model

FEBS Open Bio, EarlyView.
This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito, Haduki Asano, Ayano Ueki, Joe Sakamoto, Yasuhiro Kamei, Hayato Tokumoto, Ayaka Yazawa, Shigeki Kamitani   +7 more
wiley   +1 more source

Apolipoprotein L1 genetic testing, family history of hypertension, and kidney disease in a Midwestern U.S. cohort. [PDF]

Front Nephrol
Lentine KL, Elsurer Afsar R, Clair B, Memon AA, Edwards JC, Miyata KN, Afsar B, Schnitzler M, Xiao H, Carriker A, Abu Al Rub F, Hsu CY, Muiru AN, Freedman BI, Philipneri MD, Caliskan Y.   +15 more
europepmc   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Personalized risk estimates of advanced neoplasia development in individuals with a family history of colorectal cancer. [PDF]

Fam Cancer
Greuter MJE, Akwiwu EU, Hennink SD, Bisseling TM, Spanier MBW, German Consortium for Familial Intestinal Cancer, Nagtegaal ID, Canfell K, Dekker E, Klausch T, Lansdorp-Vogelaar I, van Leerdam ME, Hoogerbrugge N, Coupé VMH.   +13 more
europepmc   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, EarlyView.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Association Between Family History in Patients with Primary Gout and Left Ventricular Diastolic Function: A Cross-Sectional Study

Wen Wen,1,* Ping Lei,1,* Wantai Dang,2 Liwen Ma,1 Jing Hu,1 Jian Liu1 1Department of Ultrasound, First Affiliated Hospital, Clinical Medical College of Chengdu Medical College, Chengdu, People’s Republic of China; 2Department of Rheumatology ...
Liu J, Ma L, Hu J, Wen W, Lei P, Dang W
core   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source